speaking of which, the management announced the completion of Pitt Hopkins in the quarterly update unlike the last one PMS which was a seperate Ann and they described it as a “groundbreaking trial”. I am wondering if this is deliberate to play it down as they sense from the open label the result may not be as good as PMS .I maybe reading too much into it and being paranoid but can’t stop thinking about this possibility
Ann: 2023 Annual Report to shareholders, page-158
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.65 |
Change
-0.540(2.81%) |
Mkt cap ! $2.383B | |||
| Open | High | Low | Value | Volume |
| $18.98 | $19.15 | $18.50 | $10.51M | 560.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $18.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.65 | 1127 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |